-
-
-
-
-
-
-
ImmunityBio, Inc. (IBRX) Tops Q4 EPS by 5c
-
-
-
-
-
-
-
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
-
-
-
-
-
-
-
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arrow Financial, ImmunityBio, Seagate, and Baxter and Encourages Investors to Contact the Firm
-
-
-
1,217,868 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

